Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;33(6):e86.
doi: 10.3802/jgo.2022.33.e86.

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

Ning Li  1 , Qi Liu  2 , Yu Tian  2 , Lingying Wu  3
Affiliations
Review

Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective

Ning Li et al. J Gynecol Oncol. 2022 Nov.

Abstract

Over the last decade, clinical trials using various poly ADP ribose polymerase (PARP) inhibitors on patients with ovarian cancer have shown promising results. The introduction of PARP inhibitors has changed the treatment landscape and improved outcomes for patients with ovarian cancer. Fuzuloparib, developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd., is a novel orally available small molecule PARP inhibitor. By introducing the trifluoromethyl group into chemical structure, fuzuloparib exhibits higher stability and lower inter-individual variability than other PARP inhibitors. Several clinical trials (FZOCUS series and others) have been carried out to assess the efficacy and safety of fuzuloparib through different lines of treatments for advanced or recurrent ovarian cancer in both treatment and maintenance. Here, we present the most recent data from these studies, discuss current progress and potential future directions.

Keywords: Fuzuloparib; Maintenance Therapy; Ovarian Cancer; PARP Inhibitor.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1
Fig. 1. Chemical structure of fuzuloparib.
Fig. 2
Fig. 2. Research and development history of fuzuloparib: expanding from gBRCAm, platinum-sensitive recurrence to first-line maintenance.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer (IARC), World Health Organization. Cancer today [Internet] Geneva: World Health Organization; 2020. [cited 2022 Oct 10]. Available from: https://gco.iarc.fr/today/home.
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. - PubMed
    1. Lai H, Guo Y, Tian L, Wu L, Li X, Yang Z, et al. Protein panel of serum-derived small extracellular vesicles for the screening and diagnosis of epithelial ovarian cancer. Cancers (Basel) 2022;14:3719. - PMC - PubMed
    1. Giornelli GH. Management of relapsed ovarian cancer: a review. Springerplus. 2016;5:1197. - PMC - PubMed
    1. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393:1240–1253. - PubMed

MeSH terms

Substances